229.02 - 234.51
169.21 - 260.10
55.82M / 54.92M (Avg.)
32.24 | 7.26
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.71%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-15.88%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-21.59%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-21.59%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-24.92%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-25.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-25.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.23%
Share reduction more than 1.5x VUZI's 0.92%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.17%
Diluted share reduction more than 1.5x VUZI's 0.92%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-78.64%
Negative OCF growth while VUZI is at 136.84%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-79.78%
Negative FCF growth while VUZI is at 123.17%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
226.57%
10Y CAGR of 226.57% while VUZI is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
250.60%
5Y CAGR of 250.60% while VUZI is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
76.70%
3Y CAGR of 76.70% while VUZI is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
91.36%
OCF/share CAGR of 91.36% while VUZI is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
1030.41%
OCF/share CAGR of 1030.41% while VUZI is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
734.85%
3Y OCF/share CAGR of 734.85% while VUZI is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
446.35%
10Y net income/share CAGR of 446.35% while VUZI is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
2047.83%
Net income/share CAGR of 2047.83% while VUZI is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
177.32%
3Y net income/share CAGR of 177.32% while VUZI is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
584.16%
Equity/share CAGR of 584.16% while VUZI is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
343.94%
Equity/share CAGR of 343.94% while VUZI is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
164.22%
Equity/share CAGR of 164.22% while VUZI is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.05%
Firm’s AR is declining while VUZI shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-21.21%
Inventory is declining while VUZI stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.05%
Asset growth of 1.05% while VUZI is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
5.88%
BV/share growth of 5.88% while VUZI is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
1.27%
We increase R&D while VUZI cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-9.72%
We cut SG&A while VUZI invests at 0.42%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.
